The consortium will develop an innovative in vitro diagnostic (IVD) test to assess the risk of developing heart failure (HF) after acute myocardial infarction (AMI). The test is based on a unique profile of long noncoding RNAs (lncRNA). In this project, the medical benefit of the IVD test will be validated in blood samples of European and Asian AMI patients. The HEARTLINC project will deliver an IVD test suitable for fast, multiplex and high throughput HF prediction.
The information contained in this website is related to the Eurostars Programme (2008-2013) and the Eurostars-2 Programme (2014-2020) which for practical reasons are referred to solely by the name of Eurostars unless stated otherwise.